NCT03850730View on ClinicalTrials.gov

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Hereditary Hemorrhagic TelangiectasiaEpistaxis
Interventions
DRUG

Pazopanib

Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study

All Listed Sponsors
collaborator

University of North Carolina

OTHER

lead

Cure HHT

OTHER

NCT03850730 - Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia | Biotech Hunter | Biotech Hunter